You are here: Industry Insights > Mallinckrodt

News List

Mallinckrodt Completes Acquisition of Ocera Therapeutics, OCR-002 americanpharmaceuticalreview
December 12, 2017
Mallinckrodt has closed the acquisition of Ocera Therapeutics, a clinical-phase biopharmaceutical company focused on the development and commercialization of novel therapeutic drugs for orphans and other serious liver diseases that have not been met
Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship americanpharmaceuticacreview
November 03, 2017
Bristol-Myers Squibb is the Founding Sponsor of BioLabs’ newest location, BioLabs@NYULangone. This BioLabs site was launched in partnership with NYU Langone Health.
Mallinckrodt to Acquire Ocera Therapeutics, OCR-002 americanpharmaceuticacreview
November 03, 2017
The FDA granted OCR-002 its Orphan Drug Designation, and the resulting seven years' exclusivity would be applied upon first approval of the drug.
Terumo BCT Expands Collaboration With Mallinckrodt to Bring More Treatment Options to Patients prnasia
September 21, 2017
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, announced today that it has expanded its collaboration with Mallinckrodt
M&As this week: Sun Pharmaceutical Industries, Northeast Pharmaceutical Group, Mallinckrodt pharmaceutical-technology
August 11, 2017
M&As this week: Sun Pharmaceutical Industries, Northeast Pharmaceutical Group, Mallinckrodt
Mallinckrodt settles US opioid drug probe for US$35 million biospectrumasia
July 14, 2017
Mallinckrodt Plc will pay US$35 million to resolve allegations that the company failed to report suspicious drug orders
Mallinckrodt Completes Sale of its Intrathecal Therapy Business to Piramal Enterprises Limited for A americanpharmaceuticalreview
March 21, 2017
Mallinckrodt has closed the sale of its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in the U.K., Piramal Critical Care, for approximately $203 million, including fixed and contingent consideration. The company's Intrathecal Th
Mallinckrodt and FTC Resolve Questcor Matter americanpharmaceuticalreview
January 20, 2017
Mallinckrodt announced that it has reached agreement with the U.S. Federal Trade Commission (FTC) to resolve, without admission of wrongdoing, the previously disclosed FTC investigation into the acquisition by Questcor Pharmaceuticals, Inc., of Synacthen®

Previous page 1 2 3 4 5 Next page